ANNALS OF THE RHEUMATIC DISEASES

ANNALS OF THE RHEUMATIC DISEASES(英文缩写 ANN RHEUM DIS),ISSN 0003-4967,eISSN 1468-2060 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。

2026 年数据 · 影响因子
24.000
JCR 分区
Q1
CAS 分区
B1
近一年发文量
0

指标来源:jcr_cas_ifqb

ISSN: 0003-4967 · eISSN: 1468-2060 · 缩写: ANN RHEUM DIS

期刊简介

暂无简介。

历年影响因子趋势

年份影响因子JCR 分区
-Q1
-Q1
-Q1
-Q1
-Q1

ANNALS OF THE RHEUMATIC DISEASES 最新收录文献

※ 中文译文由 AI 辅助生成,仅供学术参考,请以英文原文为准。

  1. Regulatory T cells and toll-like receptors: regulating the regulators.

    Regulatory T cells (Treg) play a crucial role in maintaining control of leucocytes. Several studies have shown that in vivo Treg depletion results in autoimmune syndromes like thyroiditis, gastritis, …

    查看详情 DOI
  2. Interplay between pathogenic Th17 and regulatory T cells.

    Autoimmune diseases arise from a break in tolerance toward self-antigens and are characterised by the development of pathogenic T cell populations infiltrating the target organ. Regulatory T cells pla…

    查看详情 DOI
  3. Could toll-like receptors provide a missing link in chronic inflammation in rheumatoid arthritis? Lessons from a study on human rheumatoid tissue. toll样受体是否可能在类风湿性关节炎的慢性炎症中提供缺失的环节?人类类风湿组织研究的教训

    In the last decade the development of a number of biological therapies has revolutionised the treatment of rheumatic diseases. The first and most widely used of these approaches, tumour necrosis facto…

    查看详情 DOI
  4. Update on toll-like receptor-directed therapies for human disease.

    Innate responses to microbes are mediated in large part by toll-like receptors (TLRs), which recognise a diverse range of molecules produced by viruses, bacteria and fungi. Great effort has been direc…

    查看详情 DOI
  5. Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy.

    Identification of the factors that regulate the immune tolerance and control the appearance of exacerbated inflammatory conditions is crucial for the development of new therapies of autoimmune disease…

    查看详情 DOI
  6. Systemic lupus erythematosus: new molecular targets.

    T cells from patients with systemic lupus erythematosus exhibit a notable array of defects that probably contribute to the origin and development of the disease. Such abnormalities include an abnormal…

    查看详情 DOI
  7. Disease activity assessment in SLE: do we have the right instruments?

    No new therapy has been approved for systemic lupus erythematosus (SLE) in decades. Interest in SLE by pharmaceutical and biotechnology companies has increased, leading to multiple clinical trials. Un…

    查看详情 DOI
  8. Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. 严格控制治疗类风湿性关节炎:疗效和可行性

    To evaluate the available evidence on the efficacy and feasibility of the new concept of tight control in randomised trials in patients with rheumatoid arthritis (RA). Tight control is a treatment str…

    查看详情 DOI
  9. alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs.

    alpha-Melanocyte-stimulating hormone (alpha-MSH) is a tridecapeptide derived from the proopiomelanocortin by post-translational processing. In addition to its effects on melanocytes, alpha-MSH has pot…

    查看详情 DOI
  10. Schnurri-3 is an essential regulator of osteoblast function and adult bone mass.

    Skeletal remodelling is a cyclical process where under normal physiological conditions, bone formation occurs at sites where bone resorption has previously taken place. Homeostatic remodelling of the …

    查看详情 DOI

在 ANNALS OF THE RHEUMATIC DISEASES 中搜索更多文献

支持中英文检索 · 智能翻译 · 影响因子 · PDF 下载 · AI 文献阅读

指标接近的期刊